Birgitte Bruun Rasmussen

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. ncbi [Preoperative biopsy diagnosis in suspicion of breast cancer]
    Birgitte Bruun Rasmussen
    Nordsjaellands Hospital, Patologiafdelingen, Hillerød
    Ugeskr Laeger 169:2985-7. 2007
  2. ncbi Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
    Birgitte B Rasmussen
    Department of Pathology, Nordsjaellands Hospital, Hilleroed, Denmark
    Lancet Oncol 9:23-8. 2008
  3. doi ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry
    Anne Vibeke Laenkholm
    Department of Pathology, Slagelse Hospital, Slagelse, Denmark
    Mol Oncol 6:428-36. 2012
  4. doi Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variable
    Birgitte Bruun Rasmussen
    Department of Pathology, Nordsjaellands Hospital, Hilleroed, Denmark
    Acta Oncol 47:784-8. 2008
  5. doi The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer
    Marianne Pedersen
    Department of Pathology, Roskilde Hospital, Roskilde, Denmark
    Diagn Mol Pathol 18:96-102. 2009
  6. doi Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study
    Gro L Willemoe
    Department of Pathology, Rigshospitalet, Copenhagen, Denmark
    Eur J Cancer 45:2528-36. 2009
  7. ncbi Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes
    Karen E Olsen
    Department of Pathology, Odense University Hospital, Denmark
    Acta Oncol 43:35-42. 2004
  8. doi Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications
    Maj Lis M Talman
    Department of Pathology, Nordsjaellands Hospital, Hillerød, Denmark
    Acta Oncol 47:789-94. 2008
  9. ncbi Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 25:3846-52. 2007
  10. ncbi Prognostic effect of estrogen receptor status across age in primary breast cancer
    Niels Bentzon
    Department of Breast Surgery, Herlev University Hospital, Herlev, Denmark
    Int J Cancer 122:1089-94. 2008

Detail Information

Publications13

  1. ncbi [Preoperative biopsy diagnosis in suspicion of breast cancer]
    Birgitte Bruun Rasmussen
    Nordsjaellands Hospital, Patologiafdelingen, Hillerød
    Ugeskr Laeger 169:2985-7. 2007
    ..e. atypia or suspicion of malignancy should be kept at a minimum. These diagnostic categories call for additional diagnostic procedures and thereby cause a delay in reaching the final diagnosis leading to definitive treatment...
  2. ncbi Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
    Birgitte B Rasmussen
    Department of Pathology, Nordsjaellands Hospital, Hilleroed, Denmark
    Lancet Oncol 9:23-8. 2008
    ..Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours...
  3. doi ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry
    Anne Vibeke Laenkholm
    Department of Pathology, Slagelse Hospital, Slagelse, Denmark
    Mol Oncol 6:428-36. 2012
    ..Major variations in ER measured by ligand binding assay and IHC are observed within all ESR1 copy number subgroups and other mechanisms than gene copy number seem to contribute to the ER protein content in the tumors...
  4. doi Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variable
    Birgitte Bruun Rasmussen
    Department of Pathology, Nordsjaellands Hospital, Hilleroed, Denmark
    Acta Oncol 47:784-8. 2008
    ..The analysis was introduced during the late 1990's, and was gradually intensified in the following years up to now. The present study deals with the experience with the analysis during the last 5 years, from 2002 - 2006...
  5. doi The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer
    Marianne Pedersen
    Department of Pathology, Roskilde Hospital, Roskilde, Denmark
    Diagn Mol Pathol 18:96-102. 2009
    ..In conclusion, it is possible by dual-color CISH method to demonstrate HER2 genes and chromosome 17 genes, in the same tissue section and reliably assess HER2 status. The CISH method is a very promising alternative to the FISH method...
  6. doi Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study
    Gro L Willemoe
    Department of Pathology, Rigshospitalet, Copenhagen, Denmark
    Eur J Cancer 45:2528-36. 2009
    ..Our aim was to determine whether the benefit of epirubicin versus methotrexate differs according to TIMP-1 tumour cell immunoreactivity...
  7. ncbi Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes
    Karen E Olsen
    Department of Pathology, Odense University Hospital, Denmark
    Acta Oncol 43:35-42. 2004
    ..Traditionally, in the FISH technique the result has been based on counting 60 cells. However, we found that a much less time-consuming method of counting 60 signals gave equally good results...
  8. doi Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications
    Maj Lis M Talman
    Department of Pathology, Nordsjaellands Hospital, Hillerød, Denmark
    Acta Oncol 47:789-94. 2008
    ..To compare BCA with IHC, and to report the prognosis for low-risk breast cancer patients...
  9. ncbi Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 25:3846-52. 2007
    ..To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer...
  10. ncbi Prognostic effect of estrogen receptor status across age in primary breast cancer
    Niels Bentzon
    Department of Breast Surgery, Herlev University Hospital, Herlev, Denmark
    Int J Cancer 122:1089-94. 2008
    ..This may have an impact on future designing of guidelines for adjuvant endocrine therapy beyond 5 years...
  11. doi Breast conserving treatment in Denmark, 1989-1998. A nationwide population-based study of the Danish Breast Cancer Co-operative Group
    Marianne Ewertz
    Department of Oncology, Odense University Hospital, University of Southern Denmark, Denmark
    Acta Oncol 47:682-90. 2008
    ..This formed the basis for recommending breast conserving surgery combined with radiotherapy as a standard treatment for suited breast cancer patients in Denmark...
  12. ncbi [Prognostic and predictive factors for endocrine treatment in breast carcinoma]
    Ann Søegaard Knoop
    Odense Universitetshospital, Onkologisk afdeling R, Odense C
    Ugeskr Laeger 169:2997-9. 2007
    ..New predictive factors are HER2 for predicting the effect of trastuzumab and TOP2A for predicting the effect of certain chemotherapies...
  13. ncbi [Sentinel node biopsy in breast cancer and malignant melanoma. The Danish Society of Pathologic Anatomy and Cytology]
    Birgitte Bruun Rasmussen
    Patologisk Institut, Arhus Kommunehospital, Arhus Universitetshospital, DK 8000 Arhus C
    Ugeskr Laeger 165:1251. 2003